Treatment of migraine headache pain when it is still mild to moderate in intensity improves response and reduces the risk of recurrence. An oral nonopioid analgesic such as a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. When moderate to severe migraine pain is not managed adequately with a nonopioid analgesic alone, addition of a triptan is recommended.1
Drugs for preventive treatment of migraine will be reviewed in a future issue.
ANALGESICS —...
RELEASE
The injectable GIP/GLP-1 receptor agonist tirzepatide (Mounjaro – Lilly), which was approved by the FDA in 2022 for treatment of type 2 diabetes,1 has now been approved to reduce the risk of MACE in adults with type 2 diabetes who are at high risk for these events. Tirzepatide is also available as Zepbound for chronic weight management and for treatment of obstructive sleep apnea in adults with obesity.2,3
GLP-1 RECEPTOR AGONISTS — The injectable GLP-1 receptor agonists semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) and oral semaglutide (Rybelsus) are also approved for cardiovascular risk reduction in patients with type 2 diabetes. These drugs have reduced the risk of MACE by up to 20%.4
A CLINICAL STUDY — FDA approval of tirzepatide for the new indication was based on the results of a …